There are 449 resources available
12P - Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial
Presenter: Martin Frueh
Session: Poster Display session
15P - Furmonertinib combined with anlotinib as the first-line treatment in patients with EGFR exon 21 Leu858Arg mutation: Results from FOCUS-A study
Presenter: Baohui Han
Session: Poster Display session
16P - A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer
Presenter: Xiuning Le
Session: Poster Display session
17P - Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs
Presenter: Xue Hou
Session: Poster Display session
19P - Resistance mechanism to first-line osimertinib in EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) in China: Preliminary data from FLOURISH study
Presenter: Jianya Zhou
Session: Poster Display session
18P - Preventing CNS metastasis in EGFR-mutant NSCLC patients without baseline CNS metastasis using aumolertinib
Presenter: Fang Cun
Session: Poster Display session
20P - Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure: An interim analysis of GPS study
Presenter: Yuan-Kai Shi
Session: Poster Display session
21P - NGS and FISH for MET amplification detection in post EGFR-TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multi-center study in China
Presenter: Qian Zheng
Session: Poster Display session